📇 Rhumatologue · PARIS CEDEX 15 · (75) · Mixte
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE G POMPIDOU HEGP
20 R LEBLANC, 75908 PARIS CEDEX 15
CABINET PRIVE DU DR JACQUES MEDIONI
HOPITAL EUROPEEN GEORGES POMPIDOU 20 RUE LEBLANC, 75908 PARIS CEDEX 15
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2020
Journal of translational medicine · 2010
Abstract Background IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4. Methods MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeated single doses were administered the day after chemotherapy at D2 and D16 of the 28-day cycles of paclitaxel (80 mg/m2 at D1, D8 and D15, for 6 cycles). Blood samples were taken 13 days after the sixth and the twelfth IMP321 injections to determine sustained APC, NK and memory CD8 T cell responses. Results Thirty MBC patients received IMP321 in three cohorts (doses: 0.25, 1.25 and 6.25 mg). IMP321 induced both a sustained increase in the number and activation of APC (monocytes and dendritic cells) and an increase in the percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90% of patients with only 3 progressors at 6 months. Also, the objective tumor response rate of 50% compared favorably to the 25% rate reported in the historical control group. Conclusions The absence of toxicity and the demonstration of activity strongly support the future development of this agent for clinical use in combined first-line regimens. Trial registration ClinicalTrials.gov NCT00349934
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Llombart-Cussac A, Harper-Wynne C, Perelló A, Hennequin A, et al.
Journal of experimental & clinical cancer research : CR · 2025 · Journal Article
Ben Sassi M, Azais H, Marcaillou C, Guibert S, et al.
The New England journal of medicine · 2020 · Clinical Trial, Phase I
Wirth LJ, Sherman E, Robinson B, Solomon B, et al.
Annales de pathologie · 2020 · Journal Article
Koual M, Perkins G, Delanoy N, Crespel C, et al.
Contemporary clinical trials communications · 2017 · Journal Article
Medioni J, Brizard M, Elaidi R, Reid PF, et al.
Bulletin du cancer · 2016 · Editorial
Freyer G, Marty M, membres du groupe de travail, Blay JY, et al.
Bulletin du cancer · 2015 · English Abstract
Ezzalfani M, Dugué A, Mollevi C, Pulido M, et al.
Bulletin du cancer · 2012 · English Abstract
Teghom C, Giraud P, Menei P, Medioni J, et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011 · Clinical Trial
Hugonnet F, Fournier L, Medioni J, Smadja C, et al.
Cancer investigation · 2011 · Case Reports
Ayllon J, Beuselinck B, Morel A, Barrascout E, et al.
Journal of translational medicine · 2010 · Clinical Trial, Phase I
Brignone C, Gutierrez M, Mefti F, Brain E, et al.
Medical oncology (Northwood, London, England) · 2010 · Case Reports
Gregory T, Mir O, Medioni J, Augereau B, et al.
The Journal of urology · 2009 · Journal Article
Medioni J, Choueiri TK, Zinzindohoué F, Cho D, et al.
International journal of radiation oncology, biology, physics · 2025 · Journal Article
Alati A, Debbi K, Scher N, Meynard C, et al.
BMC cancer · 2016 · Clinical Study
Médioni J, Di Palma M, Guillot A, Spaeth D, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2014 · Clinical Trial, Phase I
Medioni J, Deplanque G, Ferrero JM, Maurina T, et al.
Bulletin du cancer · 2019 · Journal Article
Medioni J, Pickering G, Delorme C, Lansaman T, et al.
Critical reviews in oncology/hematology · 2019 · Journal Article
Bamias A, Hegele A, Medioni J, Castellano D, et al.
Expert review of anticancer therapy · 2009 · Journal Article
Oudard S, Medioni J, Aylllon J, Barrascourt E, et al.
Clinical breast cancer · 2023 · Journal Article
Medioni J, Scimeca D, Lopez Marquez Y, Leray E, et al.
Bulletin du cancer · 2012 · English Abstract
Médioni J, Guastalla JP, Drouet L
Gynecologic oncology · 2022 · Clinical Trial, Phase II
Joly F, Fabbro M, Follana P, Lequesne J, et al.
European journal of cancer (Oxford, England : 1990) · 2019 · Clinical Trial, Phase II
Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, et al.
Bulletin du cancer · 2019 · Journal Article
Medioni J, Pickering G, Delorme C, Lansaman T, et al.
Critical reviews in oncology/hematology · 2019 · Journal Article
Bamias A, Hegele A, Medioni J, Castellano D, et al.
PloS one · 2023 · Journal Article
Leroy K, Audigier Valette C, Alexandre J, Boussemart L, et al.
Critical reviews in oncology/hematology · 2019 · Journal Article
Bamias A, Hegele A, Medioni J, Castellano D, et al.
European urology · 2009 · Case Reports
Medioni J, Banu E, Helley D, Scotte F, et al.
Cancer chemotherapy and pharmacology · 2012 · Clinical Trial, Phase I
Mardjuadi F, Medioni J, Kerger J, D'Hondt L, et al.
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer
Abstract Background Epithelial ovarian cancer (EOC) is a leading cause of cancer mortality in women, often diagnosed at advanced stages. While first-line treatments improve survival, relapses remain common, with 5-year s
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer
Abstract Background Epithelial ovarian cancer (EOC) is a leading cause of cancer mortality in women, often diagnosed at advanced stages. While first-line treatments improve survival, relapses remain common, with 5-year s
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Cardiovascular and interventional radiology · 2014 · Journal Article
Pellerin O, Medioni J, Vulser C, Déan C, et al.